SV40 and p53 as team players in childhood lymphoproliferative disorders

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1307-1317

  Heinsohn, Susanne ^a   Scholz, Roswitha ^a   Kabisch, Hartmut ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

B cell acute lymphoblastic leukemia; Childhood lymphoma; Human polyomavirus; Lympho proliferative disorder; Non Hodgkin's lymphoma; Oncogenic virus; p53; Simian virus 40; Tumour suppressor gene

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA BINDING; DNA DENATURATION; EXON; GENE DOSAGE; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; INFANT; LYMPH NODE; LYMPHATIC LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NEWBORN; NONHODGKIN LYMPHOMA; NONHUMAN; NONSENSE MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIMIAN VIRUS 40;

ADOLESCENT; ANIMALS; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; COS CELLS; EXONS; GENES, P53; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOPROLIFERATIVE DISORDERS; MUTATION; SIMIAN VIRUS 40;

EID: 79955016828     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.967     Document Type: Article

References (97)

1. Jarret R: Viruses and lymphoma/leukaemia. J Pathol 208: 176-186, 2006.
2. Coles A, Marfella C, Imbalzano A, et al: P37Ing1b regulates B-cell proliferation and cooperates with p53 to suppress diffuse large B-cell lymphomagenesis. Cancer Res 68: 8705-8714, 2008.
3. Farrell P, Allan G, Shanahan F, Vousden K and Crook T: p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 10: 2879-2887, 1991. (Pubitemid 21905305)
4. Smardova J, Grochova D, Fabian P, et al: An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication. Oncol Rep 20: 773-778, 2008.
5. Hosny G, Farahat N and Hainaut P: TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma. Cancer Lett 275: 234-239, 2009.
6. Cerroni L, Zochling N, Putz B and Kerl H: Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 24: 457-461, 1997. (Pubitemid 27432373)
7. Kutting B, Bonsmann G, Metze D, Luger TA and Cerroni L: Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: Complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 36: 311-314, 1997. (Pubitemid 27078893)
8. Niedobitek G, Meru N and Delecluse H: Epstein-Barr virus infection and human malignancies. Int J Exp Pathol 82: 149-170, 2001. (Pubitemid 32718497)
9. Butel JS: Viral carcinogenesis: Revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 21: 405-426, 2000.
10. Kelly G and Rickinson A: Burkitt lymphoma: Revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 277-284, 2007.
11. Du M, Diss T, Liu H, Ye H, Hamoudi R and Cabecadas J: KSHV- and EBV-associated germinotropic lymphoproliferative dicorder. Blood 100: 3415-3418, 2002. (Pubitemid 35217095)
12. Levy LS and Bost KL: Mechanisms that contribute to the development of lymphoid malignancies: Roles for genetic alterations and cytokine production. Crit Rev Immunol 16: 31-57, 1996. (Pubitemid 26240001)
13. Moller MB, Nielsen O and Pedersen NT: Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology 41: 322-330, 2002. (Pubitemid 35279029)
14. Raphael M, Borisch B and Jaffe E: Lymphomas associated with infection by the human immune deficiency virus (HIV). In: World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H and Vardiman JW (eds). IARC, Lyon, pp260-263, 2001.
15. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A and Sanpaolo M: Hepatitis C virus and B-cell non-Hodgkin lymphomas: An Italian multicenter case-control study. Blood 102: 996-999, 2003. (Pubitemid 36917795)
16. Engels E, Chatterjee N, Cerhan J, Davis S, Cozen W and Severson R: Hepatitis C virus infection and non-Hodgkin lymphoma: Results of the NCI-SEER multi-center case-control study. Int J Cancer 111: 76-80, 2004. (Pubitemid 38859286)
17. Sangar D, Pipkin P, Wood D and Minor P: Examination of poliovirus vaccine preparations for SV40 sequences. Biologicals 27: 1-10, 1999. (Pubitemid 29381112)
18. Shah K and Nathanson N: Human exposure to SV40: review and comment. Am J Epidemiol 103: 1-12, 1976.
19. Sweet B and Hillemann M: The vacuolating virus, S.V.40. Proc Soc Exp Biol Med 105: 420-427, 1960.
20. Shein HM, Enders JF and Levinthal JD: Transformation induced by simian virus 40 in human renal cell cultures. II. Cell-virus relationships. Proc Natl Acad Sci USA 48: 1350-1357, 1962.
21. Ahuja D, Saenz-Robles M and Pipas J: SV40 large T antigen multiple cellular pathways to elicit cellular transformation. Oncogene 24: 7729-7745, 2005. (Pubitemid 41670675)
22. Diamandopoulos GT: Leukemia, lymphoma, and osteosarcoma induced in the Syrian golden hamster by simian virus 40. Science 176: 173-175, 1972.
23. Shivapurkar N, Harada K, Reddy J, et al: Presence of simian virus 40 DNA sequences in human lymphomas. Lancet 359: 651-852, 2002.
24. Vilchez RA and Butel JS: Simian virus 40 and its association with human lymphomas. Curr Oncol Rep 5: 372-379, 2003. (Pubitemid 38898806)
25. de Sanjose S, Shah KV, Domingo-Domenech E, et al: Lack of serological evidence for an association between simian virus 40 and lymphoma. Int J Cancer 104: 522-524, 2003. (Pubitemid 36323925)
26. Meneses A, Lopez-Terrada D, Zanwar P, et al: Lymphoproliferative disorders in Costa Rica and simian virus 40. Haematologica 90: 1635-1642, 2005. (Pubitemid 41814987)
27. Butel JS, Vilchez RA, Jorgensen JL and Kozinetz CA: Association between SV40 and non-Hodgkin's lymphoma. Leuk Lymphoma 44 (Suppl 3): 33-39, 2003.
28. David H, Mendoza S, Konishi T and Miller CW: Simian virus 40 is present in human lymphomas and normal blood. Cancer Lett 162: 57-64, 2001.
29. MacKenzie J, Wilson K, Perry J, Gallagher A and Jarrett R: Association between simian virus 40 DNA and lymphoma in the United Kingdom. J Natl Cancer Inst 95: 1001-1003, 2003. (Pubitemid 36896717)
30. Vilchez RA and Butel JS: Polyomavirus SV40 infection and lymphomas in Spain. Int J Cancer 107: 505-508, 2003.
31. Vilchez RA and Butel JS: Simian virus 40 infection in lymphoproliferative disorders. Lancet 361: 1565-1566, 2003. (Pubitemid 36566362)
32. + patients. Int J Cancer 78: 669-674, 1998.
33. Rizzo P, Carbone M, Fisher SG, et al: Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma. Chest 116: S0470-S473, 1999.
34. Vilchez RA, Madden CR, Kozinetz CA, et al: Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 359: 817-823, 2002. (Pubitemid 34233750)
35. Yazdi A, Puchta U, Flaig M and Sander C: Lack of evidence for the presence of Simian virus 40 DNA in cutaneous lymphomas. J Invest Dermatol 121: 212-213, 2003. (Pubitemid 36900477)
36. Capello D, Rossi D, Gaudino G, Carbone A and Gaidano G: Simian virus 40 infection in lymphoproliferative disorders. Lancet 361: 88-89, 2003. (Pubitemid 36050991)
37. Nakatsuka S, Liu A, Dong Z, et al: Simian virus 40 sequences in malignant lymphomas in Japan. Cancer Res. 63: 7606-7608, 2003. (Pubitemid 37466681)
38. Jasani B, Cristaudo A and Emri S: Association of SV40 with human tumours. Semin Cancer Biol 11: 49-61, 2001. (Pubitemid 32222751)
39. Brousset P, de Araujo V and Gascoyne R: Immunohistochemical investigation of SV40 large T antigen in Hodgkin and non-Hodgkin's lymphoma. Int J Cancer 112: 5333-5535, 2004.
40. Vilchez RA, Lopez-Terrada D, Middleton JR, et al: Simian virus 40 tumor antigen expression and immunophenotypic profile of aids-related non-Hodgkin's lymphoma. Virology 342: 38-46, 2005. (Pubitemid 41531984)
41. Heinsohn S, Golta S, Kabisch H and zur Stadt U: Standardized detection of Simian virus 40 by real-time quantitative polymerase chain reaction in pediatric malignancies. Haematologica 90: 94-99, 2005. (Pubitemid 40193759)
42. McNees AL, White ZS, Zanwar P, Vilchez RA and Butel JS: Specific and quantitative detection of human polyomaviruses BKV, JCV, and SV40 by real time PCR. J Clin Virol 34: 52-62, 2005. (Pubitemid 41125877)
43. Lane D and Crawford L: T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263, 1979. (Pubitemid 9129076)
44. Linzer D and Levine A: Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52, 1979. (Pubitemid 9188209)
45. Levine A, Momand J and Finlay C: The p53 tumour suppressor gene. Nature 351: 453-456, 1991. (Pubitemid 21896613)
46. Cowell J: The nuclear oncoproteins: RB and p53. Sem Cancer Biol 1: 437-446, 1990.
47. Lane D: P53, guardian of the genome. Nature 358: 15-16, 1992.
48. Soussi T: Focus on the p53 gene and cancer: advances in TP53 mutation research. Hum Mutat 21: 173-175, 2003.
49. Spandidos DA, Liloglou T and Field J: Prognostic significance of oncogenes and tumor suppressor genes in human malignancy. Stem Cells 11: 194-198, 1993. (Pubitemid 23150937)
50. Scholz RB, Kabisch H, Weber B, Roser K, Delling G and Winkler K: Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol 9: 125-137, 1992.
51. Scholz RB, Milde-Langosch K, Jung R, et al: Rapid screening for Tp53 mutations by temperature gradient gel electrophoresis: A comparison with SSCP analysis. Hum Mol Genet 2: 2155-2158, 1993. (Pubitemid 24003415)
52. Scholz RB, Christiansen H, Kabisch H and Winkler K: Molecular markers in the evaluation of bone neoplasms. In: Pathology of Bone and Joint Neoplasms. Helliwell TR (ed). W.B. Saunders, Philadelphia, PA, pp79-105, 1999.
53. Smock K, Nelson M, Tripp S, et al: Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children's Oncology Group. Pediatr Blood Cancer 51: 489-494, 2008.
54. Nakamura M, Shimada K, Ishida E, et al: Molecular pathogenesis of peadiatric astrocytic tumors. Neuro Oncol 9: 113-123, 2007. (Pubitemid 46580313)
55. Peller S and Rotter V: Tp53 in hematological cancer: Low incidence of mutations with significant clinical relevance. Hum Mutat 21: 277-284, 2003.
56. Preudhomme C and Fenaux P: The clinical significance of mutations of the p53 tumor suppressor gene in heamatological malignancies. Br J Haematol 98: 502-511, 1997. (Pubitemid 27386527)
57. Krug U, Ganser A and Koeffler H: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21: 3475-3495, 2002. (Pubitemid 34587717)
58. Zainuddin N, Berglund M, Wanders A, et al: Tp53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res 33: 60-66, 2009.
59. O'Shea D, O'Riain C, Taylor C, et al: The presence of TP53 mutations at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 112: 3126-3129, 2008.
60. Young K, Leroy K, Moller M, et al: Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: An international collaborative study. Blood 112: 3088-3098, 2008.
61. Sherr C: Cancer cell cycles. Science 274: 1672-1677, 1996.
62. Vogelstein B, Lane D and Levine A: Surfing the p53 network. Nature 408: 307-310, 2000.
63. Montenarh M, Kohler M and Henning R: Complex formation of simian virus 40 large T antigen with cellular protein p53. J Virol 60: 761-764, 1986. (Pubitemid 17174921)
64. McCormick F and Wood D: The role of p53 in virally associated tumors. Trends Microbiol 5: 181-182, 1997. (Pubitemid 27224527)
65. Levine A: The p53 tumor suppressor gene and gene product. Princess Takamatsu Symp 20: 221-230, 1989.
66. Hoppe-Seyler F and Butz K: Molecular mechanisms of virus-induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. J Mol Med 73: 529-538, 1995.
67. Schreier AA and Gruber J: Viral T-antigen interactions with cellular proto-oncogene and anti-oncogene products. J Natl Cancer Inst 82: 354-360, 1990. (Pubitemid 20108025)
68. Hinds P, Finlay C, Quartin R, et al: Mutant p53 clones from human colon carcinoma cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes. Cell Growth Differ 1: 571-580, 1990.
69. Levine A: The common mechanisms of tranformation by small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology 384: 285-293, 2009.
70. Amara K, Trimeche M, Ziadi S, et al: Presence of simian virus 40 in diffuse large B-cell lymphomas in Tunisia correlates with germinal center B-cell immunophenotype, t(14;18) translocation, and p53 accumulation. Mod Pathol 21: 282-296, 2008. (Pubitemid 351304282)
71. Lednicky JA and Butel JS: Consideration of PCR methods for the detection of SV40 in tissue and DNA specimens. Dev Biol Stand 94: 155-164, 1998.
72. Strickler HD: A multicenter evaluation of assays for detection of SV40 DNA and results in masked mesothelioma specimens. Cancer Epidemiol Biomarkers Prev 10: 523-532, 2001.
73. Rizzo P, Di Resta I, Powers A, et al: The detection of simian virus 40 in human tumors by polymerase chain reaction. Monaldi Arch Chest Dis 53: 202-210, 1998. (Pubitemid 28383193)
74. Heinsohn S, Scholz RB, Weber B, et al: SV40 sequences in human osteosarcoma of German origin. Anticancer Res 20: 4539-4545, 2000.
75. Caron-de-Fromentel C and Soussi T: TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4: 1-15, 1992.
76. Hollstein M, Sidransky D, Vogelstein B and Harris C: p53 mutations in human cancers. Science 253: 49-53, 1991. (Pubitemid 21917115)
77. Weyrer K, Feichtinger H, Haun M, et al: p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest 74: 279-289, 1996.
78. Sturm I, Köhne C, Wolff G, et al: Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastasis. J Clin Oncol 17: 1364-1374, 1999. (Pubitemid 29220841)
79. http://p53.free.fr/Database/p53:
80. Kawamura M, Ohnishi H, Guo S, et al: Alterations of the p53, p21, p16, p15 and RAS genesin childhood T-cell acute lymphoblastic leukemia. Leukemia 23: 115-126, 1999.
81. Zhou M, Gu L, Yeager A and Findley H: Sensitivity to Fas-mediated apoptosis in peadiatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 12: 1756-1763, 1998. (Pubitemid 28502495)
82. Stokke T, Galteland E, Holte H, et al: Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer 89: 313-324, 2000. (Pubitemid 30620283)
83. Martin A, Flaman J, Frebourg T, et al: Functional analysis of the p53 protein in AIDS-rtalated non-Hodgkin's lymphomas and polymorphic lymphoproliferations. Br J Heamatol 101: 311-317, 1998. (Pubitemid 28261119)
84. Hainaut P and Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137, 2000. (Pubitemid 29439303)
85. Joerger A and Fersht A: Structural biology of the tumor suppressor p53. Annu Rev Biochem 77: 557-582, 2008.
86. Ang H, Joerger A, Mayer S and Fersht A: Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J Biol Chem 281: 21934-21941, 2006. (Pubitemid 44181897)
87. Kato S, Han S-Y, Liu W, et al: Understanding the function-structure and function-mutation relationship of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100: 8424-8429, 2003. (Pubitemid 36842561)
88. Dearth L, Qian H, Wang T, et al: Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Cancerogenesis 28: 289-298, 2007. (Pubitemid 46321844)
89. Joerger A, Ang H, Veprintsev D, Blair C and Fersht A: Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem 280: 16030-16037, 2005. (Pubitemid 40616727)
90. Greenblatt M, Bennet W and Hollstein M: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994. (Pubitemid 24289415)
91. Neil J, Cameron E and Baxter E: p53 and tumour viruses: Catching the guardian off-guard. Trends Microbiol 5: 115-120, 1997. (Pubitemid 27139472)
92. Sheu B, Chang W, Lin H, Chow S and Huang S: Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J Obstet Gynaecol Res 33: 103-113, 2007. (Pubitemid 46380029)
93. Salarieh A, Rao C, Gottesmann S, Alagha O, Todor R and Axiotis C: Plasma cell tumors in HIV-positive patients: Report of a case and review of the literature. Leuk Lymphoma 46: 1067-1074, 2005. (Pubitemid 40975029)
94. Manenti G, Trincucci G, Pettinicchio A, Amendola E, Scarfo M and Dragani T: Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung cancer. Oncogene 27: 5753-5758, 2008.
95. Reddi H, McIver B, Grebe S and Eberhardt N: The paired box-8/peroxisome proliferator-activated receptor-y oncogene in thyroid tumorigenesis. Endocrinology 148: 932-935, 2007.
96. Carbone M, Pannuti A, Zhang L, Testa J and Bochetta M: A novel mechanism of late gene silencing drives SV40 transformation of human mesothelia cells. Cancer Res 68: 9488-9496, 2008.
97. Paquette R, Lee Y, Wilczynski S, et al: Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 72: 1272-1280, 1993. (Pubitemid 23224995)